nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—CYP2C8—Simvastatin—atherosclerosis	0.0572	0.0768	CbGbCtD
Levomilnacipran—CYP2C8—Pravastatin—atherosclerosis	0.056	0.0752	CbGbCtD
Levomilnacipran—CYP2C8—Lovastatin—atherosclerosis	0.056	0.0752	CbGbCtD
Levomilnacipran—CYP2C19—Rosuvastatin—atherosclerosis	0.0516	0.0693	CbGbCtD
Levomilnacipran—CYP2C19—Simvastatin—atherosclerosis	0.048	0.0644	CbGbCtD
Levomilnacipran—CYP2C19—Lovastatin—atherosclerosis	0.047	0.0631	CbGbCtD
Levomilnacipran—CYP2D6—Niacin—atherosclerosis	0.0461	0.062	CbGbCtD
Levomilnacipran—ABCB1—Ezetimibe—atherosclerosis	0.0416	0.0559	CbGbCtD
Levomilnacipran—ABCB1—Simvastatin—atherosclerosis	0.0387	0.052	CbGbCtD
Levomilnacipran—ABCB1—Lovastatin—atherosclerosis	0.0379	0.0509	CbGbCtD
Levomilnacipran—ABCB1—Pravastatin—atherosclerosis	0.0379	0.0509	CbGbCtD
Levomilnacipran—CYP2D6—Simvastatin—atherosclerosis	0.0365	0.049	CbGbCtD
Levomilnacipran—CYP2D6—Pravastatin—atherosclerosis	0.0357	0.0479	CbGbCtD
Levomilnacipran—CYP2D6—Lovastatin—atherosclerosis	0.0357	0.0479	CbGbCtD
Levomilnacipran—CYP3A4—Ezetimibe—atherosclerosis	0.025	0.0335	CbGbCtD
Levomilnacipran—CYP3A4—Rosuvastatin—atherosclerosis	0.025	0.0335	CbGbCtD
Levomilnacipran—CYP3A4—Simvastatin—atherosclerosis	0.0232	0.0312	CbGbCtD
Levomilnacipran—CYP3A4—Pravastatin—atherosclerosis	0.0227	0.0305	CbGbCtD
Levomilnacipran—CYP3A4—Lovastatin—atherosclerosis	0.0227	0.0305	CbGbCtD
Levomilnacipran—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00109	0.00607	CcSEcCtD
Levomilnacipran—Haematuria—Rosuvastatin—atherosclerosis	0.00107	0.00595	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.00106	0.00591	CcSEcCtD
Levomilnacipran—Disturbance in sexual arousal—Niacin—atherosclerosis	0.00105	0.00585	CcSEcCtD
Levomilnacipran—Migraine—Niacin—atherosclerosis	0.00105	0.00581	CcSEcCtD
Levomilnacipran—Urinary retention—Niacin—atherosclerosis	0.00101	0.00561	CcSEcCtD
Levomilnacipran—Hepatitis—Rosuvastatin—atherosclerosis	0.00101	0.00561	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Lovastatin—atherosclerosis	0.000985	0.00547	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Niacin—atherosclerosis	0.000981	0.00545	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.000975	0.00541	CcSEcCtD
Levomilnacipran—Dry skin—Niacin—atherosclerosis	0.000974	0.00541	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Ezetimibe—atherosclerosis	0.000966	0.00536	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Pravastatin—atherosclerosis	0.000966	0.00536	CcSEcCtD
Levomilnacipran—Dry skin—Pravastatin—atherosclerosis	0.000959	0.00532	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Lovastatin—atherosclerosis	0.000945	0.00525	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.000929	0.00516	CcSEcCtD
Levomilnacipran—Urinary tract infection—Lovastatin—atherosclerosis	0.000927	0.00514	CcSEcCtD
Levomilnacipran—Abdominal distension—Niacin—atherosclerosis	0.000924	0.00513	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Simvastatin—atherosclerosis	0.000921	0.00511	CcSEcCtD
Levomilnacipran—Abdominal distension—Pravastatin—atherosclerosis	0.00091	0.00505	CcSEcCtD
Levomilnacipran—Angina pectoris—Niacin—atherosclerosis	0.000894	0.00497	CcSEcCtD
Levomilnacipran—Mental disorder—Rosuvastatin—atherosclerosis	0.000885	0.00491	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000884	0.00491	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Simvastatin—atherosclerosis	0.000884	0.00491	CcSEcCtD
Levomilnacipran—Angina pectoris—Pravastatin—atherosclerosis	0.000881	0.00489	CcSEcCtD
Levomilnacipran—Flatulence—Rosuvastatin—atherosclerosis	0.000866	0.00481	CcSEcCtD
Levomilnacipran—Hepatitis—Lovastatin—atherosclerosis	0.000856	0.00475	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Niacin—atherosclerosis	0.000846	0.00469	CcSEcCtD
Levomilnacipran—Dysuria—Pravastatin—atherosclerosis	0.000845	0.00469	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.00084	0.00466	CcSEcCtD
Levomilnacipran—Hepatitis—Ezetimibe—atherosclerosis	0.000839	0.00466	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Pravastatin—atherosclerosis	0.000833	0.00462	CcSEcCtD
Levomilnacipran—Oedema peripheral—Ezetimibe—atherosclerosis	0.000827	0.00459	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000825	0.00458	CcSEcCtD
Levomilnacipran—Weight decreased—Pravastatin—atherosclerosis	0.000818	0.00454	CcSEcCtD
Levomilnacipran—Erythema multiforme—Lovastatin—atherosclerosis	0.000809	0.00449	CcSEcCtD
Levomilnacipran—Hepatitis—Simvastatin—atherosclerosis	0.0008	0.00444	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.000799	0.00444	CcSEcCtD
Levomilnacipran—Flushing—Lovastatin—atherosclerosis	0.000794	0.00441	CcSEcCtD
Levomilnacipran—Erythema multiforme—Ezetimibe—atherosclerosis	0.000794	0.00441	CcSEcCtD
Levomilnacipran—Urinary tract infection—Pravastatin—atherosclerosis	0.000784	0.00435	CcSEcCtD
Levomilnacipran—Flushing—Ezetimibe—atherosclerosis	0.000779	0.00432	CcSEcCtD
Levomilnacipran—Chills—Lovastatin—atherosclerosis	0.000768	0.00426	CcSEcCtD
Levomilnacipran—Angiopathy—Ezetimibe—atherosclerosis	0.000762	0.00423	CcSEcCtD
Levomilnacipran—Erythema multiforme—Simvastatin—atherosclerosis	0.000757	0.0042	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000756	0.0042	CcSEcCtD
Levomilnacipran—Flushing—Simvastatin—atherosclerosis	0.000743	0.00412	CcSEcCtD
Levomilnacipran—Mental disorder—Ezetimibe—atherosclerosis	0.000735	0.00408	CcSEcCtD
Levomilnacipran—Hepatitis—Niacin—atherosclerosis	0.000735	0.00408	CcSEcCtD
Levomilnacipran—Flatulence—Lovastatin—atherosclerosis	0.000734	0.00407	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Niacin—atherosclerosis	0.000731	0.00406	CcSEcCtD
Levomilnacipran—Malnutrition—Ezetimibe—atherosclerosis	0.000731	0.00406	CcSEcCtD
Levomilnacipran—Dysgeusia—Lovastatin—atherosclerosis	0.000729	0.00405	CcSEcCtD
Levomilnacipran—Oedema peripheral—Niacin—atherosclerosis	0.000724	0.00402	CcSEcCtD
Levomilnacipran—Hepatitis—Pravastatin—atherosclerosis	0.000724	0.00402	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Pravastatin—atherosclerosis	0.00072	0.004	CcSEcCtD
Levomilnacipran—Flatulence—Ezetimibe—atherosclerosis	0.00072	0.004	CcSEcCtD
Levomilnacipran—Chills—Simvastatin—atherosclerosis	0.000718	0.00399	CcSEcCtD
Levomilnacipran—Infection—Rosuvastatin—atherosclerosis	0.000713	0.00396	CcSEcCtD
Levomilnacipran—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000704	0.00391	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000702	0.0039	CcSEcCtD
Levomilnacipran—Vision blurred—Lovastatin—atherosclerosis	0.000702	0.0039	CcSEcCtD
Levomilnacipran—Mental disorder—Simvastatin—atherosclerosis	0.000701	0.00389	CcSEcCtD
Levomilnacipran—Tremor—Lovastatin—atherosclerosis	0.000698	0.00387	CcSEcCtD
Levomilnacipran—Eye disorder—Niacin—atherosclerosis	0.000687	0.00381	CcSEcCtD
Levomilnacipran—Flatulence—Simvastatin—atherosclerosis	0.000687	0.00381	CcSEcCtD
Levomilnacipran—Erythema multiforme—Pravastatin—atherosclerosis	0.000684	0.0038	CcSEcCtD
Levomilnacipran—Dysgeusia—Simvastatin—atherosclerosis	0.000682	0.00379	CcSEcCtD
Levomilnacipran—Flushing—Niacin—atherosclerosis	0.000682	0.00379	CcSEcCtD
Levomilnacipran—Flushing—Pravastatin—atherosclerosis	0.000672	0.00373	CcSEcCtD
Levomilnacipran—Cardiac disorder—Pravastatin—atherosclerosis	0.000672	0.00373	CcSEcCtD
Levomilnacipran—Angiopathy—Niacin—atherosclerosis	0.000667	0.0037	CcSEcCtD
Levomilnacipran—Leukopenia—Lovastatin—atherosclerosis	0.000667	0.0037	CcSEcCtD
Levomilnacipran—Chills—Niacin—atherosclerosis	0.000659	0.00366	CcSEcCtD
Levomilnacipran—Vision blurred—Simvastatin—atherosclerosis	0.000657	0.00365	CcSEcCtD
Levomilnacipran—Tremor—Simvastatin—atherosclerosis	0.000653	0.00362	CcSEcCtD
Levomilnacipran—Chills—Pravastatin—atherosclerosis	0.000649	0.0036	CcSEcCtD
Levomilnacipran—Insomnia—Rosuvastatin—atherosclerosis	0.000649	0.0036	CcSEcCtD
Levomilnacipran—Palpitations—Ezetimibe—atherosclerosis	0.000646	0.00358	CcSEcCtD
Levomilnacipran—Paraesthesia—Rosuvastatin—atherosclerosis	0.000644	0.00358	CcSEcCtD
Levomilnacipran—Malnutrition—Niacin—atherosclerosis	0.00064	0.00355	CcSEcCtD
Levomilnacipran—Chest pain—Lovastatin—atherosclerosis	0.000634	0.00352	CcSEcCtD
Levomilnacipran—Anxiety—Lovastatin—atherosclerosis	0.000632	0.00351	CcSEcCtD
Levomilnacipran—Dyspepsia—Rosuvastatin—atherosclerosis	0.000631	0.00351	CcSEcCtD
Levomilnacipran—Hypertension—Ezetimibe—atherosclerosis	0.000631	0.0035	CcSEcCtD
Levomilnacipran—Flatulence—Niacin—atherosclerosis	0.00063	0.0035	CcSEcCtD
Levomilnacipran—Tension—Niacin—atherosclerosis	0.000628	0.00349	CcSEcCtD
Levomilnacipran—Leukopenia—Simvastatin—atherosclerosis	0.000624	0.00346	CcSEcCtD
Levomilnacipran—Chest pain—Ezetimibe—atherosclerosis	0.000622	0.00345	CcSEcCtD
Levomilnacipran—Flatulence—Pravastatin—atherosclerosis	0.000621	0.00345	CcSEcCtD
Levomilnacipran—Dry mouth—Lovastatin—atherosclerosis	0.00062	0.00344	CcSEcCtD
Levomilnacipran—Tension—Pravastatin—atherosclerosis	0.000618	0.00343	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000618	0.00343	CcSEcCtD
Levomilnacipran—Dysgeusia—Pravastatin—atherosclerosis	0.000617	0.00342	CcSEcCtD
Levomilnacipran—Constipation—Rosuvastatin—atherosclerosis	0.000613	0.00341	CcSEcCtD
Levomilnacipran—Dry mouth—Ezetimibe—atherosclerosis	0.000608	0.00338	CcSEcCtD
Levomilnacipran—Infection—Lovastatin—atherosclerosis	0.000604	0.00335	CcSEcCtD
Levomilnacipran—Vision blurred—Niacin—atherosclerosis	0.000603	0.00335	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Lovastatin—atherosclerosis	0.000595	0.0033	CcSEcCtD
Levomilnacipran—Vision blurred—Pravastatin—atherosclerosis	0.000594	0.0033	CcSEcCtD
Levomilnacipran—Chest pain—Simvastatin—atherosclerosis	0.000593	0.00329	CcSEcCtD
Levomilnacipran—Infection—Ezetimibe—atherosclerosis	0.000592	0.00329	CcSEcCtD
Levomilnacipran—Anxiety—Simvastatin—atherosclerosis	0.000591	0.00328	CcSEcCtD
Levomilnacipran—Tremor—Pravastatin—atherosclerosis	0.00059	0.00328	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000587	0.00326	CcSEcCtD
Levomilnacipran—Nervous system disorder—Ezetimibe—atherosclerosis	0.000585	0.00325	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000584	0.00324	CcSEcCtD
Levomilnacipran—Anorexia—Lovastatin—atherosclerosis	0.00058	0.00322	CcSEcCtD
Levomilnacipran—Skin disorder—Ezetimibe—atherosclerosis	0.000579	0.00322	CcSEcCtD
Levomilnacipran—Syncope—Niacin—atherosclerosis	0.000574	0.00319	CcSEcCtD
Levomilnacipran—Leukopenia—Niacin—atherosclerosis	0.000573	0.00318	CcSEcCtD
Levomilnacipran—Urticaria—Rosuvastatin—atherosclerosis	0.00057	0.00316	CcSEcCtD
Levomilnacipran—Abdominal pain—Rosuvastatin—atherosclerosis	0.000567	0.00315	CcSEcCtD
Levomilnacipran—Palpitations—Niacin—atherosclerosis	0.000565	0.00314	CcSEcCtD
Levomilnacipran—Infection—Simvastatin—atherosclerosis	0.000565	0.00314	CcSEcCtD
Levomilnacipran—Leukopenia—Pravastatin—atherosclerosis	0.000564	0.00313	CcSEcCtD
Levomilnacipran—Loss of consciousness—Niacin—atherosclerosis	0.000562	0.00312	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Simvastatin—atherosclerosis	0.000557	0.00309	CcSEcCtD
Levomilnacipran—Insomnia—Lovastatin—atherosclerosis	0.00055	0.00305	CcSEcCtD
Levomilnacipran—Paraesthesia—Lovastatin—atherosclerosis	0.000546	0.00303	CcSEcCtD
Levomilnacipran—Hypertension—Pravastatin—atherosclerosis	0.000544	0.00302	CcSEcCtD
Levomilnacipran—Anorexia—Simvastatin—atherosclerosis	0.000542	0.00301	CcSEcCtD
Levomilnacipran—Dyspnoea—Lovastatin—atherosclerosis	0.000542	0.00301	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000541	0.003	CcSEcCtD
Levomilnacipran—Insomnia—Ezetimibe—atherosclerosis	0.000539	0.00299	CcSEcCtD
Levomilnacipran—Chest pain—Pravastatin—atherosclerosis	0.000536	0.00298	CcSEcCtD
Levomilnacipran—Paraesthesia—Ezetimibe—atherosclerosis	0.000535	0.00297	CcSEcCtD
Levomilnacipran—Dyspepsia—Lovastatin—atherosclerosis	0.000535	0.00297	CcSEcCtD
Levomilnacipran—Anxiety—Pravastatin—atherosclerosis	0.000534	0.00297	CcSEcCtD
Levomilnacipran—Dry mouth—Niacin—atherosclerosis	0.000533	0.00296	CcSEcCtD
Levomilnacipran—Dyspnoea—Ezetimibe—atherosclerosis	0.000532	0.00295	CcSEcCtD
Levomilnacipran—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000529	0.00293	CcSEcCtD
Levomilnacipran—Decreased appetite—Lovastatin—atherosclerosis	0.000528	0.00293	CcSEcCtD
Levomilnacipran—Dyspepsia—Ezetimibe—atherosclerosis	0.000525	0.00291	CcSEcCtD
Levomilnacipran—Fatigue—Lovastatin—atherosclerosis	0.000524	0.00291	CcSEcCtD
Levomilnacipran—Constipation—Lovastatin—atherosclerosis	0.00052	0.00289	CcSEcCtD
Levomilnacipran—Decreased appetite—Ezetimibe—atherosclerosis	0.000518	0.00288	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000515	0.00286	CcSEcCtD
Levomilnacipran—Asthenia—Rosuvastatin—atherosclerosis	0.000515	0.00286	CcSEcCtD
Levomilnacipran—Insomnia—Simvastatin—atherosclerosis	0.000514	0.00286	CcSEcCtD
Levomilnacipran—Fatigue—Ezetimibe—atherosclerosis	0.000514	0.00285	CcSEcCtD
Levomilnacipran—Shock—Niacin—atherosclerosis	0.000514	0.00285	CcSEcCtD
Levomilnacipran—Infection—Pravastatin—atherosclerosis	0.000511	0.00284	CcSEcCtD
Levomilnacipran—Paraesthesia—Simvastatin—atherosclerosis	0.000511	0.00283	CcSEcCtD
Levomilnacipran—Constipation—Ezetimibe—atherosclerosis	0.00051	0.00283	CcSEcCtD
Levomilnacipran—Tachycardia—Niacin—atherosclerosis	0.00051	0.00283	CcSEcCtD
Levomilnacipran—Pruritus—Rosuvastatin—atherosclerosis	0.000508	0.00282	CcSEcCtD
Levomilnacipran—Skin disorder—Niacin—atherosclerosis	0.000507	0.00282	CcSEcCtD
Levomilnacipran—Dyspnoea—Simvastatin—atherosclerosis	0.000507	0.00281	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Niacin—atherosclerosis	0.000505	0.0028	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Pravastatin—atherosclerosis	0.000503	0.00279	CcSEcCtD
Levomilnacipran—Dyspepsia—Simvastatin—atherosclerosis	0.000501	0.00278	CcSEcCtD
Levomilnacipran—Anorexia—Niacin—atherosclerosis	0.000498	0.00276	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000497	0.00276	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Pravastatin—atherosclerosis	0.000497	0.00276	CcSEcCtD
Levomilnacipran—Decreased appetite—Simvastatin—atherosclerosis	0.000494	0.00274	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000491	0.00273	CcSEcCtD
Levomilnacipran—Diarrhoea—Rosuvastatin—atherosclerosis	0.000491	0.00272	CcSEcCtD
Levomilnacipran—Fatigue—Simvastatin—atherosclerosis	0.00049	0.00272	CcSEcCtD
Levomilnacipran—Anorexia—Pravastatin—atherosclerosis	0.00049	0.00272	CcSEcCtD
Levomilnacipran—Hypotension—Niacin—atherosclerosis	0.000488	0.00271	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000488	0.00271	CcSEcCtD
Levomilnacipran—Constipation—Simvastatin—atherosclerosis	0.000486	0.0027	CcSEcCtD
Levomilnacipran—Urticaria—Lovastatin—atherosclerosis	0.000483	0.00268	CcSEcCtD
Levomilnacipran—Abdominal pain—Lovastatin—atherosclerosis	0.000481	0.00267	CcSEcCtD
Levomilnacipran—Body temperature increased—Lovastatin—atherosclerosis	0.000481	0.00267	CcSEcCtD
Levomilnacipran—Dizziness—Rosuvastatin—atherosclerosis	0.000474	0.00263	CcSEcCtD
Levomilnacipran—Urticaria—Ezetimibe—atherosclerosis	0.000474	0.00263	CcSEcCtD
Levomilnacipran—Insomnia—Niacin—atherosclerosis	0.000472	0.00262	CcSEcCtD
Levomilnacipran—Abdominal pain—Ezetimibe—atherosclerosis	0.000471	0.00262	CcSEcCtD
Levomilnacipran—Body temperature increased—Ezetimibe—atherosclerosis	0.000471	0.00262	CcSEcCtD
Levomilnacipran—Paraesthesia—Niacin—atherosclerosis	0.000469	0.0026	CcSEcCtD
Levomilnacipran—Dyspnoea—Niacin—atherosclerosis	0.000466	0.00258	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000465	0.00258	CcSEcCtD
Levomilnacipran—Insomnia—Pravastatin—atherosclerosis	0.000465	0.00258	CcSEcCtD
Levomilnacipran—Somnolence—Niacin—atherosclerosis	0.000464	0.00258	CcSEcCtD
Levomilnacipran—Paraesthesia—Pravastatin—atherosclerosis	0.000462	0.00256	CcSEcCtD
Levomilnacipran—Dyspepsia—Niacin—atherosclerosis	0.00046	0.00255	CcSEcCtD
Levomilnacipran—Dyspnoea—Pravastatin—atherosclerosis	0.000458	0.00254	CcSEcCtD
Levomilnacipran—Decreased appetite—Niacin—atherosclerosis	0.000454	0.00252	CcSEcCtD
Levomilnacipran—Dyspepsia—Pravastatin—atherosclerosis	0.000453	0.00251	CcSEcCtD
Levomilnacipran—Rash—Rosuvastatin—atherosclerosis	0.000452	0.00251	CcSEcCtD
Levomilnacipran—Dermatitis—Rosuvastatin—atherosclerosis	0.000452	0.00251	CcSEcCtD
Levomilnacipran—Urticaria—Simvastatin—atherosclerosis	0.000452	0.00251	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Niacin—atherosclerosis	0.000451	0.0025	CcSEcCtD
Levomilnacipran—Abdominal pain—Simvastatin—atherosclerosis	0.00045	0.0025	CcSEcCtD
Levomilnacipran—Body temperature increased—Simvastatin—atherosclerosis	0.00045	0.0025	CcSEcCtD
Levomilnacipran—Headache—Rosuvastatin—atherosclerosis	0.000449	0.00249	CcSEcCtD
Levomilnacipran—Hypersensitivity—Lovastatin—atherosclerosis	0.000448	0.00249	CcSEcCtD
Levomilnacipran—Decreased appetite—Pravastatin—atherosclerosis	0.000447	0.00248	CcSEcCtD
Levomilnacipran—Fatigue—Pravastatin—atherosclerosis	0.000443	0.00246	CcSEcCtD
Levomilnacipran—Constipation—Pravastatin—atherosclerosis	0.00044	0.00244	CcSEcCtD
Levomilnacipran—Hypersensitivity—Ezetimibe—atherosclerosis	0.000439	0.00244	CcSEcCtD
Levomilnacipran—Asthenia—Lovastatin—atherosclerosis	0.000436	0.00242	CcSEcCtD
Levomilnacipran—Pruritus—Lovastatin—atherosclerosis	0.00043	0.00239	CcSEcCtD
Levomilnacipran—Asthenia—Ezetimibe—atherosclerosis	0.000428	0.00238	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Niacin—atherosclerosis	0.000427	0.00237	CcSEcCtD
Levomilnacipran—Nausea—Rosuvastatin—atherosclerosis	0.000426	0.00237	CcSEcCtD
Levomilnacipran—Pruritus—Ezetimibe—atherosclerosis	0.000422	0.00234	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00042	0.00233	CcSEcCtD
Levomilnacipran—Hypersensitivity—Simvastatin—atherosclerosis	0.000419	0.00233	CcSEcCtD
Levomilnacipran—Diarrhoea—Lovastatin—atherosclerosis	0.000416	0.00231	CcSEcCtD
Levomilnacipran—Urticaria—Niacin—atherosclerosis	0.000415	0.0023	CcSEcCtD
Levomilnacipran—Abdominal pain—Niacin—atherosclerosis	0.000413	0.00229	CcSEcCtD
Levomilnacipran—Body temperature increased—Niacin—atherosclerosis	0.000413	0.00229	CcSEcCtD
Levomilnacipran—Urticaria—Pravastatin—atherosclerosis	0.000408	0.00227	CcSEcCtD
Levomilnacipran—Asthenia—Simvastatin—atherosclerosis	0.000408	0.00227	CcSEcCtD
Levomilnacipran—Diarrhoea—Ezetimibe—atherosclerosis	0.000408	0.00226	CcSEcCtD
Levomilnacipran—Body temperature increased—Pravastatin—atherosclerosis	0.000406	0.00226	CcSEcCtD
Levomilnacipran—Abdominal pain—Pravastatin—atherosclerosis	0.000406	0.00226	CcSEcCtD
Levomilnacipran—Pruritus—Simvastatin—atherosclerosis	0.000402	0.00223	CcSEcCtD
Levomilnacipran—Dizziness—Lovastatin—atherosclerosis	0.000402	0.00223	CcSEcCtD
Levomilnacipran—Dizziness—Ezetimibe—atherosclerosis	0.000394	0.00219	CcSEcCtD
Levomilnacipran—Diarrhoea—Simvastatin—atherosclerosis	0.000389	0.00216	CcSEcCtD
Levomilnacipran—Vomiting—Lovastatin—atherosclerosis	0.000387	0.00215	CcSEcCtD
Levomilnacipran—Hypersensitivity—Niacin—atherosclerosis	0.000385	0.00214	CcSEcCtD
Levomilnacipran—Rash—Lovastatin—atherosclerosis	0.000383	0.00213	CcSEcCtD
Levomilnacipran—Dermatitis—Lovastatin—atherosclerosis	0.000383	0.00213	CcSEcCtD
Levomilnacipran—Headache—Lovastatin—atherosclerosis	0.000381	0.00211	CcSEcCtD
Levomilnacipran—Vomiting—Ezetimibe—atherosclerosis	0.000379	0.0021	CcSEcCtD
Levomilnacipran—Hypersensitivity—Pravastatin—atherosclerosis	0.000379	0.0021	CcSEcCtD
Levomilnacipran—Dizziness—Simvastatin—atherosclerosis	0.000376	0.00209	CcSEcCtD
Levomilnacipran—Rash—Ezetimibe—atherosclerosis	0.000376	0.00209	CcSEcCtD
Levomilnacipran—Dermatitis—Ezetimibe—atherosclerosis	0.000376	0.00209	CcSEcCtD
Levomilnacipran—Asthenia—Niacin—atherosclerosis	0.000375	0.00208	CcSEcCtD
Levomilnacipran—Headache—Ezetimibe—atherosclerosis	0.000374	0.00207	CcSEcCtD
Levomilnacipran—Pruritus—Niacin—atherosclerosis	0.000369	0.00205	CcSEcCtD
Levomilnacipran—Asthenia—Pravastatin—atherosclerosis	0.000369	0.00205	CcSEcCtD
Levomilnacipran—Pruritus—Pravastatin—atherosclerosis	0.000364	0.00202	CcSEcCtD
Levomilnacipran—Vomiting—Simvastatin—atherosclerosis	0.000362	0.00201	CcSEcCtD
Levomilnacipran—Nausea—Lovastatin—atherosclerosis	0.000361	0.002	CcSEcCtD
Levomilnacipran—Rash—Simvastatin—atherosclerosis	0.000359	0.00199	CcSEcCtD
Levomilnacipran—Dermatitis—Simvastatin—atherosclerosis	0.000358	0.00199	CcSEcCtD
Levomilnacipran—Diarrhoea—Niacin—atherosclerosis	0.000357	0.00198	CcSEcCtD
Levomilnacipran—Headache—Simvastatin—atherosclerosis	0.000356	0.00198	CcSEcCtD
Levomilnacipran—Nausea—Ezetimibe—atherosclerosis	0.000354	0.00197	CcSEcCtD
Levomilnacipran—Diarrhoea—Pravastatin—atherosclerosis	0.000352	0.00195	CcSEcCtD
Levomilnacipran—Dizziness—Niacin—atherosclerosis	0.000345	0.00192	CcSEcCtD
Levomilnacipran—Dizziness—Pravastatin—atherosclerosis	0.00034	0.00189	CcSEcCtD
Levomilnacipran—Nausea—Simvastatin—atherosclerosis	0.000338	0.00188	CcSEcCtD
Levomilnacipran—Vomiting—Niacin—atherosclerosis	0.000332	0.00184	CcSEcCtD
Levomilnacipran—Rash—Niacin—atherosclerosis	0.000329	0.00183	CcSEcCtD
Levomilnacipran—Dermatitis—Niacin—atherosclerosis	0.000329	0.00183	CcSEcCtD
Levomilnacipran—Headache—Niacin—atherosclerosis	0.000327	0.00182	CcSEcCtD
Levomilnacipran—Vomiting—Pravastatin—atherosclerosis	0.000327	0.00181	CcSEcCtD
Levomilnacipran—Rash—Pravastatin—atherosclerosis	0.000324	0.0018	CcSEcCtD
Levomilnacipran—Dermatitis—Pravastatin—atherosclerosis	0.000324	0.0018	CcSEcCtD
Levomilnacipran—Headache—Pravastatin—atherosclerosis	0.000322	0.00179	CcSEcCtD
Levomilnacipran—Nausea—Niacin—atherosclerosis	0.00031	0.00172	CcSEcCtD
Levomilnacipran—Nausea—Pravastatin—atherosclerosis	0.000305	0.0017	CcSEcCtD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atherosclerosis	2.5e-05	0.000332	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—FABP4—atherosclerosis	2.48e-05	0.00033	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—LCAT—atherosclerosis	2.48e-05	0.00033	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP27A1—atherosclerosis	2.48e-05	0.00033	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—LDLRAP1—atherosclerosis	2.46e-05	0.000328	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	2.44e-05	0.000325	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—APOA4—atherosclerosis	2.44e-05	0.000324	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ABCG1—atherosclerosis	2.43e-05	0.000323	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—LCAT—atherosclerosis	2.42e-05	0.000322	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—FABP4—atherosclerosis	2.42e-05	0.000322	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—PLG—atherosclerosis	2.4e-05	0.000319	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP7A1—atherosclerosis	2.39e-05	0.000318	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	2.38e-05	0.000317	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—APOA4—atherosclerosis	2.38e-05	0.000316	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PLA2G2A—atherosclerosis	2.35e-05	0.000313	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ALOX5AP—atherosclerosis	2.35e-05	0.000313	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ALOX15—atherosclerosis	2.35e-05	0.000313	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—APOA2—atherosclerosis	2.35e-05	0.000313	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP7A1—atherosclerosis	2.34e-05	0.000311	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ABCG5—atherosclerosis	2.32e-05	0.000309	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	2.32e-05	0.000308	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PLTP—atherosclerosis	2.32e-05	0.000308	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—atherosclerosis	2.3e-05	0.000306	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—FABP4—atherosclerosis	2.28e-05	0.000304	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—LCAT—atherosclerosis	2.28e-05	0.000304	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	2.28e-05	0.000304	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—LPA—atherosclerosis	2.24e-05	0.000298	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—APOA4—atherosclerosis	2.24e-05	0.000298	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP27A1—atherosclerosis	2.21e-05	0.000294	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—HMOX1—atherosclerosis	2.21e-05	0.000294	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP7A1—atherosclerosis	2.2e-05	0.000293	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—atherosclerosis	2.18e-05	0.00029	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	2.18e-05	0.00029	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—BGN—atherosclerosis	2.17e-05	0.000289	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP27A1—atherosclerosis	2.16e-05	0.000287	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	2.16e-05	0.000287	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—APOA5—atherosclerosis	2.15e-05	0.000286	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	2.13e-05	0.000283	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—APOB—atherosclerosis	2.12e-05	0.000282	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—atherosclerosis	2.11e-05	0.000281	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PLA2G2A—atherosclerosis	2.1e-05	0.000279	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ALOX5AP—atherosclerosis	2.1e-05	0.000279	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—APOA2—atherosclerosis	2.1e-05	0.000279	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ALOX15—atherosclerosis	2.1e-05	0.000279	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	2.09e-05	0.000278	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ABCG5—atherosclerosis	2.07e-05	0.000276	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	2.07e-05	0.000275	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PLA2G1B—atherosclerosis	2.07e-05	0.000275	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—APOA2—atherosclerosis	2.05e-05	0.000272	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ALOX15—atherosclerosis	2.05e-05	0.000272	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PLA2G2A—atherosclerosis	2.05e-05	0.000272	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ALOX5AP—atherosclerosis	2.05e-05	0.000272	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	2.05e-05	0.000272	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP27A1—atherosclerosis	2.04e-05	0.000271	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	2.03e-05	0.00027	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ABCG5—atherosclerosis	2.02e-05	0.000269	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	2.02e-05	0.000269	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ABCG8—atherosclerosis	2.01e-05	0.000267	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—LTA4H—atherosclerosis	2.01e-05	0.000267	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—LPA—atherosclerosis	2e-05	0.000266	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ALOX5—atherosclerosis	2e-05	0.000266	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atherosclerosis	1.97e-05	0.000263	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—LPA—atherosclerosis	1.95e-05	0.00026	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—BGN—atherosclerosis	1.94e-05	0.000258	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ALOX5AP—atherosclerosis	1.93e-05	0.000257	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ALOX15—atherosclerosis	1.93e-05	0.000257	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PLA2G2A—atherosclerosis	1.93e-05	0.000257	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—APOA2—atherosclerosis	1.93e-05	0.000257	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	1.92e-05	0.000256	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—APOA5—atherosclerosis	1.92e-05	0.000255	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ABCG5—atherosclerosis	1.91e-05	0.000254	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—BGN—atherosclerosis	1.89e-05	0.000252	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—APOA5—atherosclerosis	1.87e-05	0.000249	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	1.86e-05	0.000248	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PLA2G1B—atherosclerosis	1.85e-05	0.000246	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	1.85e-05	0.000246	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—LPA—atherosclerosis	1.84e-05	0.000245	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	1.83e-05	0.000243	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	1.81e-05	0.000241	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	1.81e-05	0.00024	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PLA2G1B—atherosclerosis	1.8e-05	0.00024	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NAMPT—atherosclerosis	1.79e-05	0.000238	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—PPARA—atherosclerosis	1.79e-05	0.000238	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ALOX5—atherosclerosis	1.78e-05	0.000237	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—BGN—atherosclerosis	1.78e-05	0.000237	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1.78e-05	0.000237	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—LIPC—atherosclerosis	1.78e-05	0.000237	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—APOC3—atherosclerosis	1.77e-05	0.000235	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—APOA5—atherosclerosis	1.77e-05	0.000235	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—LDLR—atherosclerosis	1.76e-05	0.000234	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ALOX5—atherosclerosis	1.74e-05	0.000232	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CETP—atherosclerosis	1.72e-05	0.000229	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PLA2G1B—atherosclerosis	1.7e-05	0.000226	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—APOA1—atherosclerosis	1.68e-05	0.000223	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	1.65e-05	0.000219	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—SCARB1—atherosclerosis	1.65e-05	0.000219	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ALOX5—atherosclerosis	1.64e-05	0.000218	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	1.6e-05	0.000213	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NAMPT—atherosclerosis	1.6e-05	0.000213	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1.59e-05	0.000212	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—LIPC—atherosclerosis	1.59e-05	0.000211	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ABCG1—atherosclerosis	1.59e-05	0.000211	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—APOC3—atherosclerosis	1.58e-05	0.00021	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—LDLR—atherosclerosis	1.57e-05	0.000209	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NAMPT—atherosclerosis	1.56e-05	0.000208	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—HMGCR—atherosclerosis	1.55e-05	0.000207	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—LIPC—atherosclerosis	1.55e-05	0.000206	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—APOC3—atherosclerosis	1.54e-05	0.000205	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CETP—atherosclerosis	1.53e-05	0.000204	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—LDLR—atherosclerosis	1.53e-05	0.000204	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CETP—atherosclerosis	1.5e-05	0.000199	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—LCAT—atherosclerosis	1.49e-05	0.000199	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—FABP4—atherosclerosis	1.49e-05	0.000199	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NAMPT—atherosclerosis	1.47e-05	0.000196	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	1.47e-05	0.000196	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—SCARB1—atherosclerosis	1.47e-05	0.000195	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—APOA4—atherosclerosis	1.47e-05	0.000195	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—LIPC—atherosclerosis	1.46e-05	0.000195	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—APOC3—atherosclerosis	1.45e-05	0.000193	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—LDLR—atherosclerosis	1.44e-05	0.000192	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP7A1—atherosclerosis	1.44e-05	0.000192	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—SCARB1—atherosclerosis	1.43e-05	0.000191	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	1.43e-05	0.00019	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CETP—atherosclerosis	1.41e-05	0.000188	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.4e-05	0.000186	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—HMGCR—atherosclerosis	1.39e-05	0.000185	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ABCA1—atherosclerosis	1.39e-05	0.000184	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—HMGCR—atherosclerosis	1.35e-05	0.00018	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SCARB1—atherosclerosis	1.35e-05	0.00018	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP27A1—atherosclerosis	1.33e-05	0.000177	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	1.33e-05	0.000177	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—HMGCR—atherosclerosis	1.28e-05	0.00017	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	1.26e-05	0.000168	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	1.26e-05	0.000168	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—APOA2—atherosclerosis	1.26e-05	0.000168	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ALOX15—atherosclerosis	1.26e-05	0.000168	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—AKT1—atherosclerosis	1.26e-05	0.000167	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.25e-05	0.000166	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ABCG5—atherosclerosis	1.25e-05	0.000166	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ABCA1—atherosclerosis	1.24e-05	0.000164	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ABCA1—atherosclerosis	1.21e-05	0.000161	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—LPA—atherosclerosis	1.2e-05	0.00016	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—HMOX1—atherosclerosis	1.19e-05	0.000158	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—BGN—atherosclerosis	1.17e-05	0.000155	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—APOA5—atherosclerosis	1.15e-05	0.000153	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—APOB—atherosclerosis	1.14e-05	0.000151	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ABCA1—atherosclerosis	1.14e-05	0.000151	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	1.11e-05	0.000148	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTM1—atherosclerosis	1.11e-05	0.000147	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—LPL—atherosclerosis	1.09e-05	0.000145	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ALOX5—atherosclerosis	1.07e-05	0.000143	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—HMOX1—atherosclerosis	1.06e-05	0.000141	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GPX1—atherosclerosis	1.06e-05	0.000141	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—HMOX1—atherosclerosis	1.04e-05	0.000138	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CD36—atherosclerosis	1.03e-05	0.000137	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—APOB—atherosclerosis	1.02e-05	0.000135	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—APOB—atherosclerosis	9.92e-06	0.000132	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTM1—atherosclerosis	9.89e-06	0.000131	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—MTHFR—atherosclerosis	9.79e-06	0.00013	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—HMOX1—atherosclerosis	9.76e-06	0.00013	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—LPL—atherosclerosis	9.7e-06	0.000129	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTM1—atherosclerosis	9.65e-06	0.000128	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NAMPT—atherosclerosis	9.62e-06	0.000128	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PPARA—atherosclerosis	9.6e-06	0.000128	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—LIPC—atherosclerosis	9.56e-06	0.000127	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—APOC3—atherosclerosis	9.5e-06	0.000126	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—LPL—atherosclerosis	9.47e-06	0.000126	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GPX1—atherosclerosis	9.47e-06	0.000126	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—LDLR—atherosclerosis	9.45e-06	0.000126	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—APOB—atherosclerosis	9.35e-06	0.000124	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—AGT—atherosclerosis	9.3e-06	0.000124	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GPX1—atherosclerosis	9.24e-06	0.000123	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CETP—atherosclerosis	9.23e-06	0.000123	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CD36—atherosclerosis	9.22e-06	0.000123	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—APOE—atherosclerosis	9.11e-06	0.000121	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTM1—atherosclerosis	9.09e-06	0.000121	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CAV1—atherosclerosis	9.03e-06	0.00012	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—APOA1—atherosclerosis	9.01e-06	0.00012	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CD36—atherosclerosis	9e-06	0.00012	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—LPL—atherosclerosis	8.93e-06	0.000119	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SCARB1—atherosclerosis	8.84e-06	0.000118	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—MTHFR—atherosclerosis	8.74e-06	0.000116	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GPX1—atherosclerosis	8.71e-06	0.000116	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PPARA—atherosclerosis	8.57e-06	0.000114	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—MTHFR—atherosclerosis	8.53e-06	0.000113	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CD36—atherosclerosis	8.48e-06	0.000113	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PPARA—atherosclerosis	8.37e-06	0.000111	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HMGCR—atherosclerosis	8.34e-06	0.000111	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—AGT—atherosclerosis	8.3e-06	0.00011	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CG—atherosclerosis	8.22e-06	0.000109	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—APOE—atherosclerosis	8.13e-06	0.000108	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—AGT—atherosclerosis	8.1e-06	0.000108	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CAV1—atherosclerosis	8.06e-06	0.000107	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—APOA1—atherosclerosis	8.04e-06	0.000107	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—MTHFR—atherosclerosis	8.04e-06	0.000107	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—APOE—atherosclerosis	7.94e-06	0.000106	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PPARG—atherosclerosis	7.94e-06	0.000106	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PPARA—atherosclerosis	7.88e-06	0.000105	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CAV1—atherosclerosis	7.87e-06	0.000105	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—APOA1—atherosclerosis	7.85e-06	0.000104	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—INS—atherosclerosis	7.79e-06	0.000104	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—AGT—atherosclerosis	7.64e-06	0.000102	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—APOE—atherosclerosis	7.48e-06	9.95e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ABCA1—atherosclerosis	7.44e-06	9.89e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CAV1—atherosclerosis	7.41e-06	9.86e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—APOA1—atherosclerosis	7.4e-06	9.84e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CG—atherosclerosis	7.34e-06	9.76e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CG—atherosclerosis	7.17e-06	9.53e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ALB—atherosclerosis	7.14e-06	9.49e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PPARG—atherosclerosis	7.09e-06	9.42e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—INS—atherosclerosis	6.95e-06	9.24e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PPARG—atherosclerosis	6.92e-06	9.2e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NOS3—atherosclerosis	6.83e-06	9.08e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—INS—atherosclerosis	6.78e-06	9.02e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CG—atherosclerosis	6.75e-06	8.98e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PPARG—atherosclerosis	6.52e-06	8.67e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—INS—atherosclerosis	6.39e-06	8.5e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HMOX1—atherosclerosis	6.38e-06	8.49e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ALB—atherosclerosis	6.37e-06	8.47e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PTGS2—atherosclerosis	6.24e-06	8.3e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ALB—atherosclerosis	6.22e-06	8.27e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—APOB—atherosclerosis	6.11e-06	8.13e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NOS3—atherosclerosis	6.09e-06	8.1e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NOS3—atherosclerosis	5.95e-06	7.91e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTM1—atherosclerosis	5.95e-06	7.91e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ALB—atherosclerosis	5.86e-06	7.79e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—LPL—atherosclerosis	5.84e-06	7.76e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GPX1—atherosclerosis	5.69e-06	7.57e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NOS3—atherosclerosis	5.61e-06	7.45e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PTGS2—atherosclerosis	5.57e-06	7.41e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CD36—atherosclerosis	5.54e-06	7.37e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PTGS2—atherosclerosis	5.44e-06	7.24e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MTHFR—atherosclerosis	5.25e-06	6.99e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PPARA—atherosclerosis	5.15e-06	6.86e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PTGS2—atherosclerosis	5.13e-06	6.82e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—AGT—atherosclerosis	4.99e-06	6.64e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—APOE—atherosclerosis	4.89e-06	6.51e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CAV1—atherosclerosis	4.85e-06	6.45e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—APOA1—atherosclerosis	4.84e-06	6.43e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CG—atherosclerosis	4.41e-06	5.87e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PPARG—atherosclerosis	4.26e-06	5.67e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—INS—atherosclerosis	4.18e-06	5.56e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ALB—atherosclerosis	3.83e-06	5.1e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NOS3—atherosclerosis	3.66e-06	4.87e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PTGS2—atherosclerosis	3.35e-06	4.46e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—AKT1—atherosclerosis	3.14e-06	4.17e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—AKT1—atherosclerosis	2.8e-06	3.73e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—AKT1—atherosclerosis	2.73e-06	3.64e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—AKT1—atherosclerosis	2.58e-06	3.43e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—AKT1—atherosclerosis	1.68e-06	2.24e-05	CbGpPWpGaD
